



250,000 Results Any time ▾

Treating hepatocellular carcinoma progression following ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808569>

Over the last 5 years, **molecularly targeted therapy** has become a mainstay in the **treatment** paradigm for **advanced hepatocellular carcinoma (HCC)** [Padzur, 2012; Zhu, 2012]. **Sorafenib** was the first and remains the only approved systemic therapy for advanced HCC.

Cited by: 15

Author: A. Ruth He, Alec S. Goldenberg

Publish Year: 2013

Second-Line Treatments for Advanced Hepatocellular ...

<https://www.targetedonc.com/publications/hcc-monitor/2015/October-2015/second-line...>

Oct 13, 2015 · Zhu AX, Park JO, Ryoo BY, et al. **Ramucirumab versus placebo** as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with **sorafenib** (REACH): a randomised, double-blind, multicentre, phase 3 trial.

[PDF] Meta-Analysis Molecular targeted agents as second-line ...

[www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path\[\]=21454...](http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path[]=21454...)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review Jung Han Kim 1, Bum Jun Kim 1,2, Hyun Joo Jang 3 and Jin Lee

Author: Jung Han Kim, Bum Jun Kim, Hyun J... Publish Year: 2017

Targeted Therapies for Hepatocellular Carcinoma | Susan ...

https://www.researchgate.net/.../307088999_Targeted_Therapies_for_Hepatocellular_Carcinoma

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with **sorafenib** (REACH): A randomised, double-blind, multicentre ...

Emerging Targeted Therapies for Treatment of ...

<https://www.intechopen.com/books/hepatocellular-carcinoma-advances-in-diagnosis-and...>

Hepatocellular carcinoma (HCC) has dismal diagnosis due to the presence of underlying cirrhosis, late diagnosis, and limited treatment options. Surgery or liver transplantation is restricted to those with small tumours or well-compensated liver diseases. Despite advances in early screening and diagnosis of HCC, survival of patients has not improved greatly.


Author: Sarwat Fatima, Nikki Pui-Yue Lee, Hiu... Publish Year: 2017

DOI: 10.5772/intechopen.71480

Hepatocellular carcinoma

Medical Condition

A common type of cancer affecting liver



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

- Rare (Fewer than 200,000 cases per year in US)
- May be preventable by vaccine
- Often requires lab test or imaging
- Treatment from medical professional advised
- Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.

Symptoms

The early stages of the disease do not present any symptoms but in the later stages the symptoms which are noted are as follows:

- Upper abdominal pain
- Weight loss
- Jaundice

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 48667

Manuscript Type: REVIEW

Targeted agents for second-line treatment of advanced hepatocellular carcinoma

Personeni N *et al.* Second-line therapy for HCC

Nicola Personeni, Tiziana Pressiani, Silvia Bozzarelli, Lorenza Rimassa

Abstract

Over the past ten years, sorafenib, a multikinase inhibitor, has been the standard of care for patients with unresectable hepatocellular carcinoma (HCC) and well-preserved liver function. Recently, lenvatinib, a different multikinase inhibitor, was shown to be non-inferior to sorafenib, in terms of survival, while all other agents previously tested failed to

Match Overview

Match Number	Source	Words	Similarity
1	Internet	268 words crawled on 01-Jul-2019 www.tandfonline.com	4%
2	Crossref	187 words Andrew X Zhu, Yoon-Koo Kang, Chia-Jul Yen, Richard S Finn et al. "Ramucirumab after sorafenib in patients with adv	3%
3	Internet	119 words crawled on 02-Jun-2019 www.nejm.org	2%
4	Crossref	63 words Giandomenico Roviello, Navid Sohbani, Roberto Petrioli, Maria Grazia Rodriguez. "Ramucirumab as a second line th	1%
5	Crossref	43 words Jean-Luc Raoul, Jean-Sébastien Frenel, Judith Raimbourg, Marine Gilibert. "Current options and future possibilitie ...	1%
6	Crossref	38 words Maciej Kaweckí. "Current literature review", <i>Oncology in Clinical Practice</i> , 2018	1%
7	Crossref	31 words L Rimassa, A Cheng, F Braithe, F Benzaghoul, S Hazra, A Borgman, R Sinha, Z Kayali, A Zhu, R Kelley. "P-238Phase	<1%
8	Internet	31 words crawled on 04-Jul-2019 ir.exelixis.com	<1%
9	Internet	30 words crawled on 02-May-2019 www.stivarga-us.com	<1%
10	Internet	28 words crawled on 26-Oct-2018 gicasy.com	<1%
11	Crossref	26 words Vita, Ferdinando De. "Clinical management of advanced ... stric cancer: The role of new molecular drugs", <i>World Journ</i>	<1%

找到约 33,800,000 条结果 (用时 0.82 秒)

Google 学术: Targeted agents for second-line treatment of advanced hepatocellular carcinoma.

... -line therapy in patients with advanced hepatocellular ... - Finn - 被引用次数: 163

... for intermediate or advanced hepatocellular carcinoma ... - Bruix - 被引用次数: 170

Second-line therapies in hepatocellular carcinoma: ... - Villanueva - 被引用次数: 72

Molecular targeted agents as second-line treatment for hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731957/>  [翻译此页](#)

作者: JH Kim - 2017 - 被引用次数: 1 - [相关文章](#)

2017年11月24日 - For patients with advanced HCC, first-line treatment with sorafenib is recommended. Sorafenib is an oral, multi-targeted receptor tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF. INTRODUCTION · RESULTS · DISCUSSION · MATERIALS AND METHODS

Second-Line Treatments for Advanced Hepatocellular Carcinoma

<https://www.targetedonc.com/.../second-line-treatments-for-advanced-hepato...>  [翻译此页](#)

2015年10月13日 - Second-Line Treatments for Advanced Hepatocellular Carcinoma ... pathways, was the first agent evaluated in second-line therapy for HCC. ... oncogenic pathways that would guide selection of targeted treatment challenging.

Cabozantinib as a Second-Line Agent in Advanced Hepatocellular ...

<https://www.karger.com/Article/FullText/488542> - [翻译此页](#)

作者: M Kudo - 2018 - 被引用次数: 8 - [相关文章](#)

2018年4月17日 - Although most of the previous clinical trials of second-line agents, except ... fourth molecular-targeted drug option for hepatocellular carcinoma (HCC). with advanced hepatocellular carcinoma following first-line therapy with ...

Systemic treatment for advanced hepatocellular carcinoma - UpToDate

<https://www.uptodate.com/.../systemic-treatment-for-advanced-hepatocellula...>  [翻译此页](#)

作者: KE Stuart - 被引用次数: 3 - [相关文章](#)

2019年1月16日 - Hepatocellular carcinoma (HCC) is an aggressive tumor that usually occurs in the ... therapy) or systemic (chemotherapy, molecularly targeted therapy, as second-line treatment in patients with advanced hepatocellular ...